Shares of Aratana Therapeutics Inc. tumbled 9.1% in premarket trade Monday, after the pet therapeutics company disclosed that the Center for Veterinary Medicine requested more information about its appetite stimulation drug. Aratana said the request is related to the company's post-approval supplement request to transfer the manufacturing of Tentyce to a new vendor. The company said it now expects Entyce to be commercially available by late 2017. The stock has more than doubled over the past 12 months through Friday, while the S&P 500 has gained 22%.
Continue Reading Below
Copyright © 2017 MarketWatch, Inc.